Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation

Takashi Tagami, Hideo Yasunaga, Hiroyuki Yokota, Takashi Tagami, Hideo Yasunaga, Hiroyuki Yokota

Abstract

This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency medicine 2017. Other selected articles can be found online at http://ccforum.com/series/annualupdate2017 . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901 .

References

    1. Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated out-of-hospital cardiac arrest in Europe. Resuscitation. 2005;67:75–80. doi: 10.1016/j.resuscitation.2005.03.021.
    1. Kitamura T, Iwami T, Kawamura T, et al. Nationwide improvements in survival from out-of-hospital cardiac arrest in Japan. Circulation. 2012;126:2834–2843. doi: 10.1161/CIRCULATIONAHA.112.109496.
    1. Nichol G, Thomas E, Callaway CW, et al. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA. 2008;300:1423–1431. doi: 10.1001/jama.300.12.1423.
    1. Newman M. The chain of survival concept takes hold. JEMS. 1989;14:11–13.
    1. Callaway CW, Soar J, Aibiki M, et al. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015;132:84–S145. doi: 10.1161/CIR.0000000000000273.
    1. Soar J, Nolan JP, Bottiger BW, et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support. Resuscitation. 2015;95:100–147. doi: 10.1016/j.resuscitation.2015.07.016.
    1. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884–890. doi: 10.1056/NEJMoa013029.
    1. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016;374:1711–1722. doi: 10.1056/NEJMoa1514204.
    1. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. Circulation. 2000;102:I112–128. doi: 10.1161/01.CIR.102.17.e112.
    1. Herlitz J, Ekstrom L, Wennerblom B, et al. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival? Resuscitation. 1997;33:199–205. doi: 10.1016/S0300-9572(96)01018-0.
    1. Harrison EE. Lidocaine in prehospital countershock refractory ventricular fibrillation. Ann Emerg Med. 1981;10:420–423. doi: 10.1016/S0196-0644(81)80309-5.
    1. Weaver WD, Fahrenbruch CE, Johnson DD, Hallstrom AP, Cobb LA, Copass MK. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation. 1990;82:2027–2034. doi: 10.1161/01.CIR.82.6.2027.
    1. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871–878. doi: 10.1056/NEJM199909163411203.
    1. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970;39:657–667. doi: 10.1111/j.1476-5381.1970.tb09891.x.
    1. Pantazopoulos IN, Troupis GT, Pantazopoulos CN, Xanthos TT. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J Cardiol. 2011;3:169–176. doi: 10.4330/wjc.v3.i6.169.
    1. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol. 1993;109:157–163. doi: 10.1111/j.1476-5381.1993.tb13546.x.
    1. Kondoh K, Hashimoto H, Nishiyama H, et al. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol. 1994;23:674–680. doi: 10.1097/00005344-199404000-00024.
    1. Sen L, Cui G, Sakaguchi Y, Singh BN. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs. J Pharmacol Exp Ther. 1998;285:687–694.
    1. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol. 1997;29:688–692. doi: 10.1016/S0735-1097(96)00559-1.
    1. Tsagalou EP, Anastasiou-Nana MI, Charitos CE, et al. Time course of fibrillation and defibrillation thresholds after an intravenous bolus of amiodarone – an experimental study. Resuscitation. 2004;61:83–89. doi: 10.1016/j.resuscitation.2003.12.003.
    1. Huang J, Skinner JL, Rogers JM, Smith WM, Holman WL, Ideker RE. The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. J Am Coll Cardiol. 2002;40:375–383. doi: 10.1016/S0735-1097(02)01942-3.
    1. Amino M, Yoshioka K, Opthof T, et al. Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. J Cardiovasc Pharmacol. 2010;55:391–398. doi: 10.1097/FJC.0b013e3181d3dcc7.
    1. Harayama N, Nihei S, Nagata K, et al. Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. J Anesth. 2014;28:587–592. doi: 10.1007/s00540-013-1775-5.
    1. Ji XF, Li CS, Wang S, Yang L, Cong LH. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. Resuscitation. 2010;81:1031–1036. doi: 10.1016/j.resuscitation.2010.04.023.
    1. Amino M, Inokuchi S, Nagao K, et al. Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24-hour survival in cardiopulmonary arrest patients: The SOS-KANTO 2012 Study. J Cardiovasc Pharmacol. 2015;66:600–609. doi: 10.1097/FJC.0000000000000310.
    1. SOS-KANTO 2012 Study group Changes in pre- and in-hospital management and outcomes for out-of-hospital cardiac arrest between 2002 and 2012 in Kanto, Japan: the SOS-KANTO 2012 Study. Acute Med Surg. 2015;2:225–233. doi: 10.1002/ams2.102.
    1. Amino M, Inokuchi S, Yoshioka K, et al. Does antiarrhythmic drug during cardiopulmonary resuscitation improve the one-month survival: The SOS-KANTO 2012 Study. J Cardiovasc Pharmacol. 2016;68:58–66. doi: 10.1097/FJC.0000000000000388.
    1. Tagami T, Matsui H, Ishinokami S, et al. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. Resuscitation. 2016;109:127–132. doi: 10.1016/j.resuscitation.2016.08.017.
    1. Tagami T, Matsui H, Tanaka C, et al. Amiodarone compared with lidocaine for out-of-hospital cardiac arrest with refractory ventricular fibrillation on hospital arrival: a nationwide database study. Cardiovasc Drugs Ther. 2016;30:485–491. doi: 10.1007/s10557-016-6689-7.
    1. Tagami T, Matsui H, Fushimi K, Yasunaga H. Changes in therapeutic hypothermia and coronary intervention provision and in-hospital mortality of patients with out-of-hospital cardiac arrest: a nationwide database study. Crit Care Med. 2016;44:488–495. doi: 10.1097/CCM.0000000000001401.
    1. Huang Y, He Q, Yang M, Zhan L. Antiarrhythmia drugs for cardiac arrest: a systemic review and meta-analysis. Crit Care. 2013;17:R173. doi: 10.1186/cc12852.
    1. Amino M, Yoshioka K, Kanda S, et al. Systematic review of the use of intravenous amiodarone and nifekalant for cardiopulmonary resuscitation in Japan. J Arrhyth. 2014;30:180–185. doi: 10.1016/j.joa.2013.10.001.
    1. Sanfilippo F, Corredor C, Santonocito C, et al. Amiodarone or lidocaine for cardiac arrest: A systematic review and meta-analysis. Resuscitation. 2016;107:31–37. doi: 10.1016/j.resuscitation.2016.07.235.
    1. Laina A, Karlis G, Liakos A, et al. Amiodarone and cardiac arrest: Systematic review and meta-analysis. Int J Cardiol. 2016;221:780–788. doi: 10.1016/j.ijcard.2016.07.138.
    1. Sugiyama K, Kashiura M, Hamabe Y. Amiodarone and lidocaine for shock refractory ventricular fibrillation or ventricular tachycardia in out-of-hospital cardiac arrest: are they really effective? J Thorac Dis. 2016;8:E791–E793. doi: 10.21037/jtd.2016.06.59.
    1. Ho AF, Ong ME. Antiarrhythmic drugs in out-of-hospital cardiac arrest-what does the Amiodarone, Lidocaine, or Placebo Study tell us? J Thorac Dis. 2016;8:E604–E606. doi: 10.21037/jtd.2016.05.25.
    1. Joglar JA, Page RL. Out-of-hospital cardiac arrest – are drugs ever the answer? N Engl J Med. 2016;374:1781–1782. doi: 10.1056/NEJMe1602790.
    1. Kudenchuk PJ, Daya M, Dorian P, Resuscitation Outcomes Consortium I Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016;375:802–803.
    1. Weisfeldt ML, Becker LB. Resuscitation after cardiac arrest: a 3-phase time-sensitive model. JAMA. 2002;288:3035–3038. doi: 10.1001/jama.288.23.3035.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj